Eden Research Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Sean Smith

Chief executive officer

UK£577.0k

Total compensation

CEO salary percentage	50.1%
CEO tenure	10.2yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sean Smith's remuneration changed compared to Eden Research's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-UK£2m
Mar 31 2024	n/a	n/a	-UK£4m
Dec 31 2023	UK£577k	UK£289k	-UK£6m
Sep 30 2023	n/a	n/a	-UK£7m
Jun 30 2023	n/a	n/a	-UK£7m
Mar 31 2023	n/a	n/a	-UK£5m
Dec 31 2022	UK£360k	UK£273k	-UK£2m
Sep 30 2022	n/a	n/a	-UK£2m
Jun 30 2022	n/a	n/a	-UK£2m
Mar 31 2022	n/a	n/a	-UK£2m
Dec 31 2021	UK£739k	UK£253k	-UK£3m
Sep 30 2021	n/a	n/a	-UK£3m
Jun 30 2021	n/a	n/a	-UK£3m
Mar 31 2021	n/a	n/a	-UK£3m
Dec 31 2020	UK£421k	UK£235k	-UK£2m
Sep 30 2020	n/a	n/a	-UK£2m
Jun 30 2020	n/a	n/a	-UK£2m
Mar 31 2020	n/a	n/a	-UK£1m
Dec 31 2019	UK£349k	UK£212k	-UK£1m
Sep 30 2019	n/a	n/a	-UK£594k
Jun 30 2019	n/a	n/a	-UK£44k
Mar 31 2019	n/a	n/a	-UK£189k
Dec 31 2018	UK£353k	UK£190k	-UK£335k
Sep 30 2018	n/a	n/a	-UK£1m
Jun 30 2018	n/a	n/a	-UK£2m
Mar 31 2018	n/a	n/a	-UK£1m
Dec 31 2017	UK£258k	UK£147k	-UK£639k

Compensation vs Market: Sean's total compensation ($USD731.56K) is above average for companies of similar size in the German market ($USD474.43K).

Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.

CEO

Sean Smith (57 yo)

10.2yrs

Tenure

UK£577,046

Compensation

Mr. Sean Michael Smith has been the Chief Executive Officer of Eden Research PLC since September 1, 2014. Mr. Smith served as the Head of Europe and Innovation Advisor at Intellectual Ventures - Invention...

Board Members

Name	Position	Tenure	Compensation	Ownership
Sean Smith	CEO & Executive Director	10.2yrs	UK£577.05k	0.22% € 49.9k
Alexander Abrey	CFO, Secretary & Executive Director	17.2yrs	UK£433.42k	0.33% € 74.3k
Gary Ostroff	Member of Scientific Advisory Board	no data	no data	no data
Robin James Cridland	Independent Non-Executive Director	9.5yrs	UK£40.00k	0.14% € 31.2k
Lykele van der Broek	Independent Non-Executive Chairman	7.1yrs	UK£45.00k	0.30% € 67.9k
Richard Smart	Member of Scientific Advisory Board	no data	no data	no data
Paul Williams	Member of Scientific Advisory Board	no data	no data	no data
Chung-Jan Chang	Member of Scientific Advisory Board	no data	no data	no data
Derek McAllan	Non-Executive Director	less than a year	no data	0.061% € 13.5k

9.5yrs

Average Tenure

57yo

Average Age

Experienced Board: 9T7's board of directors are considered experienced (9.5 years average tenure).

Eden Research Management

Management criteria checks 1/4

Key information

Recent management updates

Eden Research plc Announces Executive Changes

Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing Lead

Eden Research plc Appoints Humair Tariq as New Global Commercial Lead

Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGM

Insufficient new directors

Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive Director

Recent updates

New major risk - Financial position

Eden Research Delists from the OTCQB Exchange in the US

First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.015 loss in 1H 2023)

Eden Research plc to Report First Half, 2024 Results on Sep 23, 2024

Eden Research plc Announces Temporary Approval for Cedroz in Greece

Eden Research plc Announces Executive Changes

Eden Research plc Announces Biofungicide Regulatory Authorisation in Germany

Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing Lead

Eden Research plc Announces Biofungicide Label Extension in Spain

Eden Research plc Appoints Humair Tariq as New Global Commercial Lead

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)

Eden Research plc to Report Fiscal Year 2023 Results on May 07, 2024

Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGM

New major risk - Revenue and earnings growth

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.006 loss in FY 2022)

New minor risk - Financial data availability

Insufficient new directors

Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive Director

Eden Research plc Provides Revenue Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.003 loss in 1H 2022)

Eden Research plc to Report First Half, 2023 Results on Sep 29, 2023

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Eden Research plc Announces Regulatory Application for Authorised Use of Ecovelex™ in the United Kingdom

Eden Research plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: UK£0.006 loss per share (vs UK£0.007 loss in FY 2021)

Eden Research plc to Report Fiscal Year 2022 Results on May 05, 2023

Eden Research plc Announces First Mevalone Authorisation for Domestic Use

Eden Research plc Provides Revenue Guidance for the Full Year of 2022

Less than half of directors are independent

First half 2022 earnings released: EPS: UK£0 (vs UK£0.004 loss in 1H 2021)

Eden Research plc Grants US EPA Regulatory Approval

Eden Research plc Appoints Richard Horsman as Non-Executive Director, with effect from 1 September 2022

Eden Research plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in FY 2020)

Eden Research plc Announces Progress Towards EPA Approval and Further Authorisation in Italy

Insufficient new directors

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.004 loss in 1H 2020)

Eden Research plc Announces New Label Extension for Biofungicide in Portugal

Full year 2020 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in FY 2019)

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age